Progress of studies on antidiabetic drugs for promoting insulin secretions

Chinese Pharmaceutical Journal

Volumn 40, Issue 6, 2005, Pages 408-410

  Liu, Jian Chao ^a   Ji, Ru Yun ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,1 DIMETHYL 2 (2 MORPHOLINOPHENYL)GUANIDINE FUMARATE; 2 (2 IMIDAZOLIN 2 YL) 1,4 DIISOPROPYLPIPERAZINE; 4 (4 METHYLCYCLOHEXYL) 4 OXOBUTYRIC ACID; 4 HYDROXYISOLEUCINE; ACX; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; MEGLITINIDE; MITIGLINIDE; NATEGLINIDE; REPAGLINIDE; UNCLASSIFIED DRUG;

ARTICLE; DRUG MECHANISM; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS;

EID: 22044432559     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Mikhailov MV, Mikhailova EA, Ashcro SJH. Molecular structure of the glibenclamide binding site of the β-cell KATP channel[J]. FEBS Lett, 2000, 499: 154.
2. Kenji S, Kazuku S, Katsnmi K, et al. (R)-ACX is a novel sulfonylurea compound with potent, quick and short-lasting hypoglycemic activity[J]. Eur J Pharmacol, 2000, 389(2-3): 253.
3. Grell W, Hurnaus R, Griss G, et al. Repaglinide and related hypoglycemic benzoic acid derivatives[J]. J Med Chem, 1998, 41(26): 5219.
4. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group[J]. Diabetes Care, 1999, 22(3): 463.
5. Owens DR, Cozma LS, Luzio SD. Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide[J]. Diabetes Nutr Metab, 2002, 15(6 Suppl): 19.
6. Verges B. The impact of prandial glucose regulation in practice[J]. Diabetes Nutr Metab, 2002, 15(6 Suppl): 28.
7. Broca C, Gross R, Petit P, et al. 4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties[J]. Am J Physiol, 1999, 277: E617.
8. Whitelaw DC, Clark PM, Smith JM. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in type 2 diabetes mellitus[J]. Diabetes Med, 2000, 17(3): 225.
9. Hanefeld M, Bouter KP, Dickinson S, et al. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia[J]. Diabetes Care, 2000, 23(2): 202.
10. Chachin M, Yamada M, Fujita A. Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K (ATP) channels[J]. J Pharmcol Exp Ther, 2003, 304(3): 1025.
11. Hu S, Boettcher BR, Dunning BE. The mechanisms underlying the unique pharmacodynamics of nateglinide[J]. Diabetologia, 2003, 46 (Suppl1): M37.
12. Halas CJ. Nateglinide[J]. Am J Health Syst Pharm, 2001, 58(13): 1200.
13. Hollander PA, Schwartz SL, Gatlin MR, et al. Importance of early insulin secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes[J]. Diabetes Care, 2001, 24(6): 983.
14. Walter YH, Spratt DI, Garreffa S, et al. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus[J]. Eur J Clin Pharmacol, 2000, 56(2): 129.
15. Saloranta C, Hershon K, Ball M, et al. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia[J]. J Clin Endocrinol Metab, 2002, 87(9): 4171.
16. Reimann F, Proks P, Ashcroft FM. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel[J]. Br J Pharmacol, 2001, 132(7): 1542.
17. Misawa K, Ichikawa K, Ojima K, et al. Effect of KAD-1229, a non-sulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs[J]. Pharmacology, 2001, 62 (2): 65.
18. Gregorio F, Ambrosi F, Boemi M, et al. Effects of S 21403 on hormone secretion from isolated rat pancreas at different glucose concentrations[J]. Eur J Pharmacol, 2002, 456(1-3): 141.
19. Ichikawa K, Yamato T, Ojima K, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats[J]. Clin Exp Pharmacol Physiol, 2002, 29(5-6): 423.
20. 1, 1999-10-21.
21. Gregorio SM, Perez Ulpiano ME, Manuel BZ. Azacycloalkane derivatives, their preparation and their application in therapy[P]. World Intellectual Property Organization: 9634870, 1999-02-09.
22. Micheline K, Philippe M, Liliane D. Pharmaceutical composition containing 4-oxo-butynic acids[P]. World Intellectual Property Organization: 9807681, 2000-11-07.
23. Itabashi N, Okada K, Muto S, et al. A novel enhancer of insulinotrophic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta-cells via a new cellular mechanism[J]. J Pharmacol Exp Ther, 2001, 297(3): 953.
24. 2+ signaling in rat islet beta-cells: strict regulation by glucose, link to insulin release, and cooperation with glucagon-like peptide-1 (7-36) amide and pituitary adenylate cyclase-activating polypeptide[J]. J Pharmacol Exp Ther, 2001, 296(1): 22.
25. 2+ influx by phosphodiesterase inhibition[J]. Br J Pharmacol, 2000, 129(5): 901.
26. Kitajima H, Nakamura M, Tamakawa H, et al. Hybridization of non-sulfonylurea insulin secretagogue and thiazolidinedione-derived insulin sensitizer[J]. Bioorg Med Chem Lett, 2000, 10(21): 2453.